Article Details
Retrieved on: 2021-06-04 05:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Truist Securities cut their price target on shares of PTC Therapeutics from $75.00 to $65.00 and set a "buy" rating for the company in a research report ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here